Home / Health / Dana-Farber Shifts Breast Care to Beth Israel
Dana-Farber Shifts Breast Care to Beth Israel
16 Oct
Summary
- Dana-Farber transitions breast oncology services from Brigham to Beth Israel next week.
- Outpatient services at Dana-Farber, surgeries at Beth Israel Deaconess Medical Center.
- This marks the first major shift as Dana-Farber unwinds its Brigham partnership by 2028.
Beginning next week, Dana-Farber Cancer Institute will transfer its breast oncology services from Brigham and Women's Hospital to Beth Israel Deaconess Medical Center (BIDMC), marking a significant evolution in its partnership with Beth Israel, which commenced in 2023. Under this new arrangement, Dana-Farber will manage outpatient breast oncology care, while BIDMC will perform breast cancer surgeries. This move signifies the initial phase of Dana-Farber's strategic disentanglement from its prior affiliation with Brigham, a process set to conclude in 2028.
Dr. Elizabeth Mittendorf, who previously worked at Brigham, has now joined BIDMC to lead its new breast surgery division, alongside several other surgeons who also transitioned from Brigham. This collaboration aims to provide comprehensive, tailored care for various breast cancer subtypes. Dana-Farber and Beth Israel are also preparing to construct a new $1.68 billion cancer hospital, expected to open in 2031, to further enhance inpatient treatment capabilities.
